Key result
Intramyocardial injection of Mesp1-marked cardiac progenitor cells significantly improved left ventricular ejection fraction to 62% compared to 41% with PBS at 6 weeks post-myocardial infarction in mice.
Why the study?
Does intramyocardial injection of Mesp1-marked cardiac progenitor cells improve survival and cardiac function in a mouse model of myocardial infarction?
Does intramyocardial injection of Mesp1-marked cardiac progenitor cells improve survival and cardiac function in a mouse model of myocardial infarction?
Absolute Event Rate: 62% vs 41%
p-value: p=<0.05
Mesp1-marked cardiac progenitor cells can successfully engraft, differentiate into cardiovascular lineages, and improve survival and cardiac function in a mouse model of myocardial infarction.
Hypothesis-generating in murine MI; requires large-animal validation before clinical translation.
Mesp1 directs multipotential cardiovascular cell fates, even though it's transiently induced prior to the appearance of the cardiac progenitor program. Tracing Mesp1-expressing cells and their progeny allows isolation and characterization of the earliest cardiovascular progenitor cells. Studying the biology of Mesp1-CPCs in cell culture and ischemic disease models is an important initial step toward using them for heart disease treatment. Because of Mesp1's transitory nature, Mesp1-CPC lineages were traced by following EYFP expression in murine Mesp1(Cre/+); Rosa26(EYFP/+) ES cells. We captured EYFP+ cells that strongly expressed cardiac mesoderm markers and cardiac transcription factors, but not pluripotent or nascent mesoderm markers. BMP2/4 treatment led to the expansion of EYFP+ cells, while Wnt3a and Activin were marginally effective. BMP2/4 exposure readily led EYFP+ cells to endothelial and smooth muscle cells, but inhibition of the canonical Wnt signaling was required to enter the cardiomyocyte fate. Injected mouse pre-contractile Mesp1-EYFP+ CPCs improved the survivability of injured mice and restored the functional performance of infarcted hearts for at least 3 months. Mesp1-EYFP+ cells are bona fide CPCs and they integrated well in infarcted hearts and emerged de novo into terminally differentiated cardiac myocytes, smooth muscle and vascular endothelial cells.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2016) studied Myocardial infarction (n=24). Mesp1-marked cardiac progenitor cells vs. PBS was evaluated on Left ventricular ejection fraction at 6 weeks (p=<0.05). Intramyocardial injection of Mesp1-marked cardiac progenitor cells significantly improved left ventricular ejection fraction to 62% compared to 41% with PBS at 6 weeks post-myocardial infarction in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: